Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E2FW | ISIN: US87241J2033 | Ticker-Symbol: 0K30
München
31.10.24
08:07 Uhr
2,180 Euro
+0,390
+21,79 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TFF PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
TFF PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,5501,85009:00

Aktuelle News zur TFF PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.09.TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery157FORT WORTH, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the "Company" or "TFF Pharmaceuticals"), a clinical-stage biopharmaceutical company focused on developing...
► Artikel lesen
11.09.TFF Pharmaceuticals enters pact for dry powder mRNA-based Covid treatment1
11.09.TFF Pharmaceuticals partners with Emory University on antiviral tech1
11.09.TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID1
10.09.TFF Pharmaceuticals reports progress in universal flu vaccine1
10.09.TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization77TFF-dry powder HA antigen vaccine candidates induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains Ongoing funded work to assess additional influenza strains FORT WORTH...
► Artikel lesen
15.08.TFF Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary-
14.08.TFF Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
06.08.TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection135Patient enrollment has accelerated, now with 13 patients enrolled in trial TFF TAC at ~20% of the oral tacrolimus dose prevented acute rejection and achieved >80% of the previous oral trough blood...
► Artikel lesen
06.08.TFF Pharmaceuticals, Inc. - 8-K, Current Report1
29.06.TFF Pharmaceuticals, Inc. - 8-K, Current Report-
26.06.TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities2
14.06.TFF Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
07.06.TFF Pharmaceuticals, Inc. - 8-K, Current Report1
21.05.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 21.05.20242.454The following instruments on Boerse Frankfurt do have their last trading day on 21.05.2024.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.05.2024.ISIN NameCA00379L1067 ABRASILV....
► Artikel lesen
20.05.TFF Pharmaceuticals, Cleveland Clinic to Advance Multiple Influenza Vaccines1
20.05.TFF Pharmaceuticals, Cleveland Clinic advance influenza vaccine candidates into preclinical testing1
20.05.TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing156FORT WORTH, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the "Company" or "TFF Pharmaceuticals"), a clinical-stage biopharmaceutical company focused on developing...
► Artikel lesen
17.05.TFF Pharmaceuticals, Inc. - 8-K, Current Report1
15.05.TFF Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary1
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1